Cargando…
Artesunate enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant chronic myeloid leukemia K562/ADR cells
Adriamycin (ADR) is a widely used drug in multiple cancers including leukemia. Artesunate (ART) has been reported to improve the cytotoxicity of some chemotherapeutic drugs in cancers. However, it is still unknown whether ART can augment the cytotoxicity of ADR in ADR-resistant K562 leukemia cells (...
Autores principales: | Chen, Li, Wang, Chao, Hu, Ning, Zhao, Hongmian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Royal Society of Chemistry
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9087932/ https://www.ncbi.nlm.nih.gov/pubmed/35547242 http://dx.doi.org/10.1039/c8ra08041k |
Ejemplares similares
-
TUG1 knockdown enhances adriamycin cytotoxicity by inhibiting glycolysis in adriamycin-resistant acute myeloid leukemia HL60/ADR cells
por: Chen, Li, et al.
Publicado: (2019) -
Naringenin suppresses K562 human leukemia cell proliferation and ameliorates Adriamycin-induced oxidative damage in polymorphonuclear leukocytes
por: LI, RUI-FANG, et al.
Publicado: (2015) -
Ophiobolin-O Reverses Adriamycin Resistance via Cell Cycle Arrest and Apoptosis Sensitization in Adriamycin-Resistant Human Breast Carcinoma (MCF-7/ADR) Cells
por: Sun, Wenxia, et al.
Publicado: (2013) -
Cytotoxicity of adriamycin to tumour cells in vivo and in vitro.
por: Martin, W. M., et al.
Publicado: (1980) -
Adriamycin/cyclophosphamide and adriamycin/melphalan in advanced L1210 leukaemia.
por: Tobias, J. S., et al.
Publicado: (1975)